ah 6809 has been researched along with cp 544326 in 1 studies
| Studies (ah 6809) | Trials (ah 6809) | Recent Studies (post-2010) (ah 6809) | Studies (cp 544326) | Trials (cp 544326) | Recent Studies (post-2010) (cp 544326) |
|---|---|---|---|---|---|
| 163 | 1 | 49 | 6 | 2 | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganesh, T | 1 |
1 review(s) available for ah 6809 and cp 544326
| Article | Year |
|---|---|
Prostanoid receptor EP2 as a therapeutic target.
Topics: Animals; Anti-Inflammatory Agents; Eye Diseases; Gene Knockout Techniques; Humans; Molecular Targeted Therapy; Neurodegenerative Diseases; Prostaglandin-Endoperoxide Synthases; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; Stroke | 2014 |